Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated with the ...

The APPLY-PNH and APPOINT-PNH studies demonstrated that iptacopan significantly improved quality of life and global health status for PNH patients, with notable improvements in cognitive ...

Dr Weitz discusses the studies on iptacopan, pegcetacoplan, and danicopan presented at ASH 2024, highlighting their effectiveness in treating PNH. Iptacopan demonstrated significant improvements ...